Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
Nothing Generic About This ETF's Long-Term Outlook
Allergan Again A Core Holding At UBS
FDA OKs expanded use of Teva's ProAir RespiClick (Seeking Alpha)
Related NVS
The Market In 5 Minutes: Sometimes It Snows In April
Benzinga's Top Upgrades
Samuel Isaly Trades in Health Care Stocks in –st Quarter (GuruFocus)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

View Comments and Join the Discussion!